Antipsychotic induced weight gain in schizophrenia:mechanisms and management

References

• McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62: 23–29
   PubMed Web of Science ®Google Scholar
• Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. Atypical antipsychotics and visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci 2004; 74: 1999–2008
   PubMed Web of Science ®Google Scholar
• Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Adv Psychiatr Treat 2005; 11: 125–132
   Google Scholar
• Reist C, Mintz J, Albers L, Jamal MM, Szabo S, Ozdemir V. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol 2007; 27: 46–51
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1–93
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005; 353: 1209–1223
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore LJ, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 2003; 37: 55–61
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003; 59: 19–27
   PubMed Web of Science ®Google Scholar
• Bai YM, Lin CC, Chen JY, Lin CY, Su TP, Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163: 1276–1279
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Consensus worldwide definition of the metabolic syndrome 2006. Belgium: International Diabetes Foundation. [cited 3 October 2007.] Available from URL: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf.
   Google Scholar
• Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480–491
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 2007; 90: 162–173
   PubMed Web of Science ®Google Scholar
• Herva A, Laitinen J, Miettunen J, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes 2006; 30: 520–527
   PubMed Web of Science ®Google Scholar
• Berkowitz RI, Fabricatore AN. Obesity, psychiatric status, and psychiatric medications. Psychiatr Clin North Am 2005; 28: 39–54
   PubMed Web of Science ®Google Scholar
• Weiss F. Group psychotherapy with obese disordered-eating adults with body-image disturbances: an integrated model. Am J Psychother 2004; 58: 281–303
   PubMedGoogle Scholar
• Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes 1998; 106: 7–9
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57
   PubMed Web of Science ®Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–567
   PubMed Web of Science ®Google Scholar
• Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psychiatric Res 2001; 101: 277–288
   PubMed Web of Science ®Google Scholar
• Ravussin E, Lillioja S, Knowler WC. Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 1988; 318: 467–472
   PubMed Web of Science ®Google Scholar
• Sharpe JK, Byrne NM, Stedman TJ, Hills AP. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105: 612–615
   PubMedGoogle Scholar
• Sharpe JK, Stedman T, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management Aust N Z J Psychiatry 2006; 40: 810–814
   Google Scholar
• Graham KA, Perkins DO, Edwards LJ, Barrier RC jR, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118–123
   PubMed Web of Science ®Google Scholar
• Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159: 1055–1057
   PubMed Web of Science ®Google Scholar
• De Vry J, Schreiber R. Effects of selected serotonin 5-HT1 and 5HT2 receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 1999; 24: 341–353
   Web of Science ®Google Scholar
• Meguid MM, Fetissov SO, Varma M, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843–857
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic induced weight gain: mechanisms and genetics. J Psychopharmacol 2006; 20: 15–18
   PubMedGoogle Scholar
• Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358–363
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007; 104: 3456–3459
   PubMed Web of Science ®Google Scholar
• Park YM, Chung YC, Lee SH, et al. Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 394–397
   Web of Science ®Google Scholar
• Yang LH, Chen TM, Yu ST, Chen YH. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007; 56: 202–208
   PubMed Web of Science ®Google Scholar
• Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N. Psychiatric medication induced obesity: an aetiologic review. Obes Rev 2004; 5: 167–170
   PubMedGoogle Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65: 47–56
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kuwaja MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–690
   PubMed Web of Science ®Google Scholar
• Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863–887
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086–2087
   PubMed Web of Science ®Google Scholar
• Buckland PR, Hoogendoorn B, Guy CA, et al. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005; 162: 613–615
   PubMed Web of Science ®Google Scholar
• Mulder H, Franke B, van der-Beek AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338–343
   PubMed Web of Science ®Google Scholar
• Ellingrod VL., Perry PJ, Ringold JC, et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 76–78
   Web of Science ®Google Scholar
• Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1021–1028
   PubMed Web of Science ®Google Scholar
• Bozina N, Medved V, Kuzman MR, Sain I, Sertic J. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 2007; 21: 728–734
   PubMed Web of Science ®Google Scholar
• Musil RL, Spellmann I, Riedel M, et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics. Eur Neuropsychopharmacol 2006; 16: S414–S415
   Web of Science ®Google Scholar
• Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7: 1681–1695
   PubMed Web of Science ®Google Scholar
• Corell CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004; 174: 477–489
   PubMed Web of Science ®Google Scholar
• Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001; 62: 843–848
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742–749
   PubMed Web of Science ®Google Scholar
• Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312–314
   PubMed Web of Science ®Google Scholar
• Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76–80
   PubMed Web of Science ®Google Scholar
• Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005; 30: 184–191
   PubMed Web of Science ®Google Scholar
• Herran A, Garcia-Unzueta MT, Amado JA, et al. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 2001; 179: 59–62
   PubMed Web of Science ®Google Scholar
• Baptista T, Dávila A, El Fakih Y, et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 2007; 22: 205–211
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol 2003; 23: 323–327
   PubMed Web of Science ®Google Scholar
• Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs?. Can J Psychiatry 2002; 47: 742–749
   PubMed Web of Science ®Google Scholar
• Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003; 65: s333–347
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004; 184: 58–62
   PubMed Web of Science ®Google Scholar
• Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller del D. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007; 40: 57–62
   PubMedGoogle Scholar
• Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007; 27: 246–251
   PubMed Web of Science ®Google Scholar
• Popovic V, Doknic M, Maric N, et al. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007; 85: 249–256
   PubMed Web of Science ®Google Scholar
• Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl) 2004; 172: 230–232
   PubMed Web of Science ®Google Scholar
• Theisen FM, Gebhardt S, Brömel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 112: 1411–1416
   PubMed Web of Science ®Google Scholar
• Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005; 30: 106–110
   PubMed Web of Science ®Google Scholar
• Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Serum ghrelin levels with BMI and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract 2005; 1: 60–64
   Web of Science ®Google Scholar
• Fadel J, Bubser M, Deutch AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22: 6742–6746
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J. The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol 2003; 18: 551–557
   PubMed Web of Science ®Google Scholar
• Baptista T, Lacruz A, de Mendonza S, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81–88
   PubMed Web of Science ®Google Scholar
• Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62: 19–28
   PubMed Web of Science ®Google Scholar
• Haupt DW, Newcomer JW. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce M, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95–102
   PubMed Web of Science ®Google Scholar
• Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125–135
   PubMed Web of Science ®Google Scholar
• Lambert TJR, Chapman LH on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004;181:544–548.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Zhang ZJ, Sun J, et al. Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 2006; 60: 1309–1313
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.
   PubMed Web of Science ®Google Scholar
• Faulkner F, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; (1):CD 005148.
   Web of Science ®Google Scholar
• Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effects of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002; 22: 68–70
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235–242
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994–1003
   PubMed Web of Science ®Google Scholar
• Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005; 162: 954–962
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115: 101–105
   PubMed Web of Science ®Google Scholar
• Binkley K, Knowles SR. Sibutramine and panic attacks. Am J Psychiatry 2002; 159: 1793–1794
   PubMed Web of Science ®Google Scholar
• Cordeiro Q, Vallada H. Sibutramine induced manic episode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5: 283–284
   PubMed Web of Science ®Google Scholar
• Taflinski T, Chojnacka J. Sibutramine-associated psychotic episode. Am J Psychiatry 2000; 157: 2057–2058
   PubMed Web of Science ®Google Scholar
• Sanofi Aventis. Acomplia 20 mg film-coated tablets. Summary of product characteristics. UK: National Institute of Clinical Excellence. [cited 1 October 2007.] Available from URL: http://www.nice.org.uk/guidance/index.jsp?action_article&o_385.15.
   Google Scholar
• Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007; 47: 642–652
   PubMed Web of Science ®Google Scholar
• Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002; 53: 842–847
   PubMed Web of Science ®Google Scholar
• Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 211–217
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28: 169–175
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163: 2072–2079
   PubMed Web of Science ®Google Scholar
• Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006; 51: 192–196
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99–108
   PubMed Web of Science ®Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655–657
   PubMed Web of Science ®Google Scholar
• Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005; 15: 13–21
   PubMed Web of Science ®Google Scholar
• Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005; 162: 1744–1746
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007; 91: 169–177
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioural intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1253–1260
   PubMed Web of Science ®Google Scholar
• Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005; 66: 205–212
   PubMed Web of Science ®Google Scholar
• Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007; 58: 544–550
   PubMed Web of Science ®Google Scholar
• Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003; 35: 237–241
   PubMed Web of Science ®Google Scholar
• Soo Kwon J, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical Trial. J Clin Psychiatry 2006; 67: 547–553
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005; 39: 479–486
   PubMed Web of Science ®Google Scholar
• Pendlebury J, Bushe CJ, Wildgust HJ, Holt RIG. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007; 115: 286–294
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001; 161: 218–227
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry 2007; 68: 34–39
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23: 595–600
   PubMed Web of Science ®Google Scholar
• Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004; 70: 57–62
   PubMed Web of Science ®Google Scholar
• Koponen H, Larmo I. Reversal of antipsychotic-induced weight gain during quetiapine treatment. Int Clin Psychopharmacol 2003; 18: 355–356
   PubMed Web of Science ®Google Scholar
• Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007; 27: 365–368
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003; 166: 391–399
   PubMed Web of Science ®Google Scholar
• Lin SK, Chen CK. Reversal of antipsychotic induced weight gain, hyperprolactinaemia and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry 2006; 67: 1307
   PubMed Web of Science ®Google Scholar
• Andersen TH, Bech P, Larsen NE. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss. Nord J Psychiatry 2005; 59: 205–208
   PubMed Web of Science ®Google Scholar
• Peuskens J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 2000; 4: 5–9
   Google Scholar
• Counterweight Project Team. A new evidence based model for weight management in primary care: the Counterweight Programme. J Hum Nutr Diet 2004; 17:191–208.
   PubMed Web of Science ®Google Scholar
• Cohn T, Sernyak M. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492–501
   PubMed Web of Science ®Google Scholar
• Mackin P, Bishop DR, Watkinson HM. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007; 7: 28
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349
   PubMed Web of Science ®Google Scholar
• Expert Group. Schizophrenia and Diabetes 2003 Expert Consensus Meeting, Dublin 3–4 October 2003: consensus summary. Br J Psychiatry 2004; 184:s112–s114.
   Web of Science ®Google Scholar
• Woo V, Harris SB, Houlden RL on behalf of the Clinical and Scientific section, Canadian Diabetes Association. Canadian Diabetes Association position paper: antipsychotic medications and associated risks of weight gain and diabetes. Can J Diabetes 2005; 29:111–112.
   Google Scholar
• De Nayer A, De Hert M. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Encephale 2007; 33: 197–202
   PubMed Web of Science ®Google Scholar
• Arranz B, San L, Duenas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 2007; 22: 11–15
   PubMed Web of Science ®Google Scholar
• Weissman EM, Moot DM, Essock SM. What do people with schizophrenia think about weight management?. Psychiatr Serv 2006; 57: 724–725
   PubMed Web of Science ®Google Scholar
• Ussher M, Stanbury L, Cheeseman V, Faulkner G. Physical activity preferences and perceived barriers to activity among persons with severe mental illness in the United Kingdom. Psychiatr Serv 2007; 58: 405–408
   PubMed Web of Science ®Google Scholar